SAN DIEGO—John Nuss, Chief Scientific Officer of Ventyx Biosciences , Inc. (NASDAQ:VTYX), recently sold 1,887 shares of the company’s common stock. The shares were sold at a price of $1.07 each, totaling approximately $2,019. This transaction took place on April 2, 2025, as disclosed in a recent SEC filing.
The sale was conducted to satisfy tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. Following this transaction, Nuss retains ownership of 467,226 shares in the company. While the company maintains a strong balance sheet with more cash than debt and a healthy current ratio, InvestingPro analysis reveals 12 additional key insights about VTYX’s financial health and valuation, available exclusively to subscribers.
In other recent news, Ventyx Biosciences, Inc. shared mixed results from a Phase 2 trial of its drug candidate VTX958 for Crohn’s disease. The drug did not meet its primary endpoint but showed promising endoscopic responses and reductions in inflammatory markers. Additionally, Ventyx has commenced Phase 2 trials for its NLRP3 inhibitor portfolio, including VTX3232 and VTX2735, targeting diseases such as obesity, cardiometabolic conditions, and recurrent pericarditis. The company expects results from these trials in 2025. Ventyx has also expanded its Scientific Advisory Board by adding seven new members, enhancing its research capabilities in neurodegenerative and cardiometabolic diseases. These experts are expected to guide the clinical development of Ventyx’s oral NLRP3 inhibitors. Furthermore, Ventyx’s cash reserves stand at $252.9 million as of December 31, 2024, which is projected to fund operations into the second half of 2026. The company continues to advance its pipeline of oral therapies for autoimmune and inflammatory conditions, with ongoing trials and developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.